Open AccessTraining patients for self‐administration of a new subcutaneous C1‐inhibitor concentrate for hereditary angioedema
Author(s) -
Murphy Elyse,
Donahue Christine,
Omert Laurel,
Persons Stephanie,
Tyma Thomas J.,
Chiao Joseph,
Lumry William
Publication year - 2019
Publication title -
nursing open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.55
H-Index - 12
ISSN - 2054-1058
DOI - 10.1002/nop2.194
Subject(s) - hereditary angioedema , medicine , angioedema , clinical trial , intervention (counseling) , nursing , physical therapy , intensive care medicine , dermatology
Aims The aim of this study was to provide recommendations for training patients with hereditary angioedema, based on nursing clinical trial experience, to self‐administer subcutaneous C1‐INH (C1‐INH[SC]) used as routine prophylaxis. Background A volume‐reduced, subcutaneous C1‐INH concentrate (C1‐INH(SC); HAEGARDA®; CSL Behring) was recently FDA‐approved for the routine prevention of hereditary angioedema attacks. Nurses will play an important role in patient training. Design Review of a phase 3, randomized, placebo‐controlled, double‐blind, crossover trial of C1‐INH(SC) (COMPACT) and summary of recommendations for training patients based on nurses’ “hands‐on experience.” Methods A panel of nurses with clinical trial experience provided recommendations for patient training. Results Practical suggestions and guidelines were compiled regarding patient selection, product reconstitution and administration and patient follow‐up. Successful patient self‐administration of C1‐INH(SC) can be greatly facilitated by qualified nursing intervention. The information provided in this paper will be useful to nurses anywhere who have an opportunity to interact with patients dealing with hereditary angioedema.